BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

Danaher (DHR) is back in focus after its latest trading session, with the stock closing at $211.50. Investors are weighing this move against the company’s recent total return profile and current fundamentals. See our latest analysis for Danaher. The recent 1 day share price return of 5.97% at US$211.50 comes after a mixed stretch, with a 90 day share price return of 22.02% but a year to date share price return that is down 8.20%. The 1 year total shareholder return of 0.79% signals only...

Danaher stock is coming off a mixed five year stretch, with the share price down 23.5%, and the latest checks suggest the shares are not an obvious bargain even though the Discounted Cash Flow (DCF) estimate points to a level close to the current market price. At the same time, traditional market multiples lean on the expensive side, which leaves investors weighing a fairly valued intrinsic estimate against a richer read on earnings based pricing. Over the past five years, Danaher has...

The safest Vanguard funds can help you through a volatile market by adding stability to your portfolio at low cost.

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Danaher (NYSE:DHR) and the rest of the research tools & consumables stocks fared in Q2.

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Danaher stock now sits around US$194.78 after a weak earnings update and a leadership change on the horizon, and investors are weighing a Discounted Cash Flow (DCF) intrinsic value estimate that points to upside against market multiples that still flag the shares as expensive. Over the past 5 years, Danaher shares have declined about 27.1%, which means long term holders are still under water even before considering valuation. The sharp selloff after the recent earnings miss and the planned...

Danaher Corporation recently reported second-quarter 2026 results showing higher sales and earnings versus a year earlier, confirmed modest third-quarter revenue growth guidance, completed multi-billion-dollar share repurchases, and announced that Executive Vice President Julie Sawyer Montgomery will become President and CEO on October 1, 2026, following Rainer Blair’s retirement and advisory transition. Sawyer Montgomery’s track record of expanding Danaher’s Diagnostics platform, including...

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation’s (NYSE:DHR) […]

Danaher Corporation (NYSE:DHR) delivered second-quarter results on July 21, marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Despite beating earnings estimates, raising its adjusted EPS guidance, and reporting improving trends in its Life Sciences business, investors remain unconvinced following weaker-than-expected bioprocessing revenue and […]

The executive has led Danaher’s diagnostics business, where she helped triple operating profit during her tenure and oversaw the recent acquisition of Masimo.

Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]

Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]

TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

Water analytics and treatment company Veralto (NYSE:VLTO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 7.5% year on year to $1.47 billion. Its non-GAAP profit of $1.11 per share was 10.3% above analysts’ consensus estimates.

Danaher (DHR) has attracted investor attention after issuing third quarter 2026 revenue guidance of 2% to 3% growth, alongside detailing recent share repurchases and releasing its latest quarterly earnings figures. See our latest analysis for Danaher. Despite Danaher's latest guidance, earnings update, and completion of multi year buyback programs, the stock has been under pressure in 2026, with the share price down 16.9% year to date and the 5 year total shareholder return also negative. If...

Danaher (NYSE:DHR) shares saw a sharp post earnings selloff, with heavy trading activity highlighting strong investor reaction. Following the drop, the stock closed near its daily highs, pointing to easing selling pressure and interest from buyers. The combination of intense volatility and late session stabilization has put Danaher back in focus for many shareholders. Danaher is a large science and technology company with businesses across diagnostics, life sciences, and environmental...

The company delivered a mixed earnings report, but the sell-off looks like an overreaction.

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.

The ruling keeps a major patent judgment in place while a separate trade-secret dispute moves to appeal.

Danaher's (DHR) Q2 results were mixed, with the lumpier part of its bioprocess consumables business

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Apple Loses Key Court Bid in $634 Million Apple Watch Blood Oxygen Dispute

To say Danaher Corp. had a downbeat reaction to earnings is an understatement. Danaher had its worst day in two decades on Tuesday after the life sciences and diagnostics company’s second-quarter earnings. Danaher expects core revenue (a metric that excludes things like currency and acquisitions) to increase between 2% and 3% for the third quarter, and Danaher narrowed its full-year forecast to 3% to 4% growth from the prior 3% to 6% expectation.

The Morning Bull - US Market Morning Update Wednesday, Jul, 22 2026 US stock futures are pointing higher, with key contracts linked to the S&P 500 up about 0.5% and Nasdaq 100 futures up roughly 1.3%, as investors weigh fresh inflation worries against easing rate fears abroad. In the US, the 10 year Treasury yield sits near 4.6%, and markets see roughly a 50 to 60% chance of a Federal Reserve rate hike in September, which matters for mortgage costs, credit cards and growth focused stocks. At...

Non-respiratory growth accelerated 150 basis points as life sciences recovered.

Shares of diversified science and technology company Danaher (NYSE:DHR) fell 13.3% in the morning session after it reported underwhelming second-quarter results. The negative reaction appeared to stem from underlying concerns about the company's profitability. While revenue grew 5.5% year over year to $6.27 billion and adjusted earnings per share of $1.94 beat estimates, the company's adjusted operating margin contracted significantly to 18%, a steep drop of 9.3 percentage points from the same q

(Updates with market moves at the end of the day.) US equities advanced Tuesday after a three-day

The AI trade is back as investors shrug off fears about a slew of cheap Chinese large-language models.

US equity indexes ended higher on Tuesday as semiconductor stocks led gains in the technology sector

Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the company's weak full-year guidance ahead of its upcoming earnings report, alongside concerns over project delays highlighted by industry peer Danaher. The cautious outlook amplified bearish sentiment before Repligen's second-quarter results, expected on July 28. The guidance signaled expectations for slower growth and tougher near-term conditions. Adding to th

Find insight on Novartis, Danaher and more in the latest Market Talks covering the health care sector.

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so

DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.